

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5952134

| | |
|---|-------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| F. HOFFMAN-LA ROCHE AG | 08/05/2019 |
| RECEIVING PARTY DATA | |
| Name: | FEDORA PHARMACEUTICALS INC. |
| Street Address: | 11629-105 AVENUE |
| City: | EDMONTON, ALBERTA |
| State/Country: | CANADA |
| Postal Code: | T5H 0L9 |
| Name: | MEIJI SEIKA PHARMA CO., LTD. |
| Street Address: | 2-4-16, KYOBASHI, CHUO-KU |
| City: | TOKYO |
| State/Country: | JAPAN |
| Postal Code: | 104-8002 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 16140601 |
| CORRESPONDENCE DATA | |
| Fax Number: | (202)721-8215 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | (202) 721-8200 |
| Email: | wlp@wenderoth.com |
| Correspondent Name: | WENDEROTH, LIND & PONACK, L.L.P |
| Address Line 1: | 1025 CONNECTICUT AVE NW., SUITE 500 |
| Address Line 4: | WASHINGTON, D.C. 20036 |
| ATTORNEY DOCKET NUMBER: | 2019-1256 |
| NAME OF SUBMITTER: | MICHAEL A. TOMPKINS |
| SIGNATURE: | /Michael A. Tompkins/ |
| DATE SIGNED: | 02/07/2020 |
| Total Attachments: 4 | |

source=Assignment#page1.tif
source=Assignment#page2.tif
source=Assignment#page3.tif
source=Assignment#page4.tif

ASSIGNMENT

WHEREAS,

F. Hoffman-La Roche AG, a corporation having an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (hereinafter "ASSIGNOR"), has acquired the entire right, title and interest in and to the invention entitled:

CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND PRODUCTION PROCESS THEREOF

and the patent applications listed in the APPENDIX attached hereto by virtue of an assignment from the inventors Michael KAMMERER and Frederic RAN to the ASSIGNOR dated December 18, 2017;

AND WHEREAS Fedora Pharmaceuticals Inc., a corporation having an office and place of business at 11629-105 Avenue, Edmonton, Alberta, T5H 0L9 Canada and Meiji Seika Pharma Co., Ltd. a corporation having an office and place of business at 2-4-16, Kyobashi, Chuo-ku, Tokyo 104-8002 Japan (hereinafter jointly "ASSIGNEE") wish to acquire the ASSIGNOR'S entire right, title and interest in and to said invention and patent applications and any Letters Patent to be obtained therefore;

NOW, THEREFORE, for and in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the ASSIGNOR hereby sells, assigns and transfers to the ASSIGNEE, its successors and assigns, the entire right, title and interest for all countries in and to the invention disclosed in the aforesaid applications, and in and to the said applications, all patent applications based upon said applications, all divisionals, continuations, or renewals thereof, all Letters Patent which may be granted therefrom, and all reissues or extensions of such patents, and in and to any and all applications which have been or shall be filed in any foreign countries for Letters Patent on the said invention including an assignment of all rights under the provisions of the International Convention, and all Letters Patent of foreign countries which may be granted therefrom; and the ASSIGNOR hereby authorizes and requests the Commissioner of Patents to issue any and all United States Letters Patent for the aforesaid invention to the ASSIGNEE of the entire right, title and interest in and to the same, for the use of the ASSIGNEE, its successors and assigns.

THE ASSIGNOR hereby agrees that the ASSIGNOR, its executors and legal representatives will without charge but at the expense of the ASSIGNEE do all things which may be necessary or legally required to vest in the ASSIGNEE, its successors or assigns the entire right, title and interest in and to the said invention, applications, Letters Patent, rights, titles, benefits, privileges and advantages hereby sold, assigned and conveyed, or intended so to be.

THE ASSIGNOR represents and agrees with said ASSIGNEE its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by the ASSIGNOR, and that full right to convey the same as herein expressed is possessed by the ASSIGNOR.



IN TESTIMONY WHEREOF, the ASSIGNOR has hereunto set its hand on the dates indicated below.

F. Hoffmann-La Roche AG

[Signature]
Signature

Basel, August 5, 2019
Date

Dirk Halbig Susanne Amann
Printed Name

Vice Director Mandatory
Title or Position

ASSIGNMENT ACCEPTED on behalf of Fedora Pharmaceuticals Inc.:

Jan 28/20 *[Signature]*
Date Signature
Christopher Michael
Printed Name
President & CEO
Title or Position

ASSIGNMENT ACCEPTED on behalf of Meiji Seika Pharma Co., Ltd.:

1/22/2020 *[Signature]*
Date Signature
Daikichiro KOBAYASHI
Printed Name
President
Title or Position

Legalization

The undersigned Notary Public of the Canton of Basel-Stadt (Switzerland), Dr. Christoph Nertz, herewith legalizes the overleaf signature of

F. Hoffmann-La Roche AG, a stock company with legal domicile in Basel (Switzerland), rendered by

Mister Dr. Dirk Halbig, German citizen, residing in Efringen-Kirchen (Germany), and

Miss Susanne Amann, German citizen, residing in Heitersheim (Germany),

both duly entitled to sign documents wherein property of the company is alienated.

Signers and signatures personally known.

B a s e l (Switzerland), this 6th (sixth) day of August 2019 (two thousand and nineteen).



BR 802/2019

APPENDIX

| Attorney Ref. No. | Country | Application Number Filing Date | Title |
|---------------------|---------|---|--|
| PR19-1255 P34326 | US | 62/563,809 Filed Sept. 27, 2017 | Crystalline Forms of Diazabicyclooctane Derivatives and Production Process Thereof |
| 2019-1256 P34326 | US | 16/140,601 Filed Sept. 25, 2018 | Crystalline Forms of Diazabicyclooctane Derivatives and Production Process Thereof |
| 2019-1257 P34326 | WO | PCT/IB2018/001204 Filed Sept. 25, 2018 | Crystalline Forms of Diazabicyclooctane Derivatives and Production Process Thereof |